Rein Therapeutics Capital Expenditures (CapEx) Growth & History (RNTX)

Rein Therapeutics's capital expenditures (capex) was $157,000 for fiscal 2021.

View full Rein Therapeutics company overview

Rein Therapeutics annual capital expenditures (capex) history

Rein Therapeutics annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20212021-12-31$157,000$152,000+3040.00%
20202020-12-31$5,000−$146,000−96.69%
20192019-12-31$151,000−$4.3M−96.59%
20182018-12-31$4.4M$4.3M+3014.79%
20172017-12-31$142,000
20152015-12-31$94,000

Rein Therapeutics capital expenditures (capex) trends

Between the periods ended 2015-12-31 and 2021-12-31, Rein Therapeutics's capital expenditures (capex) increased from $94,000 to $157,000, a change of $63,000. The latest reported quarter, Q4 2021, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Rein Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about RNTX yet. Start the conversation.

Write the first post